Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

in response to

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

KayakerBC

posted on Jan 28, 2023 09:47PM

Companies can apply for early registration with 30% or greater ORR. As of the the AGM, 27 Oct 2022, there was 2 of 11 trials showing greater than 30% ORR. With 9 companies participating in those trials and one additional trial started since the AGM it wouldn't surprise me to see one of these companies try to tie up this technology before this years end. If my memory is correct, at the AGM DM said one of these 2 trials was at 30% ORR and the other at 40%.